
  
    
      
        Background_NNP
        Fibronectin_NNP can_MD control_VB many_JJ aspects_NNS of_IN cell_NN behavior_NN ,_,
        including_VBG cell_NN growth_NN ,_, migration_NN and_CC differentiation_NN [_NN 1_CD ]_NN
        ._. Fibronectin_NNP exists_VBZ in_IN the_DT blood_NN as_IN a_DT dimer_NN ,_, but_CC in_IN
        tissues_NNS it_PRP is_VBZ in_IN the_DT form_NN of_IN an_DT insoluble_JJ fibrillar_NN matrix_NN ._.
        The_DT fibrillar_NN form_NN of_IN fibronectin_NN is_VBZ thought_VBN to_TO be_VB the_DT most_RBS
        relevant_JJ form_NN in_IN vivo_NN because_IN this_DT is_VBZ the_DT form_NN with_IN which_WDT
        most_JJS cells_NNS interact_NN [_NN 1_CD ]_NN ._. Various_JJ lines_NNS of_IN evidence_NN
        suggest_VBP that_IN the_DT fibrillar_NN matrix_NN form_NN of_IN fibronectin_NN
        exerts_NNS effects_NNS on_IN cells_NNS that_WDT are_VBP not_RB duplicated_VBN by_IN the_DT
        dimeric_JJ form_NN of_IN fibronectin_NN ._. For_IN example_NN ,_, high_JJ
        concentrations_NNS of_IN dimeric_JJ fibronectin_NN enhance_VB cell_NN
        migration_NN whereas_IN high_JJ concentrations_NNS of_IN fibrillar_NN
        fibronectin_NN reduce_VB cell_NN migration_NN [_NN 2_CD ]_NN ._. Also_RB ,_, inhibition_NN
        of_IN fibronectin_NN matrix_NN assembly_NN has_VBZ been_VBN shown_VBN to_TO inhibit_VB
        cell_NN growth_NN in_IN various_JJ systems_NNS [_NN 3_CD 4_CD 5_CD ]_NN ._. These_DT findings_NNS
        suggest_VBP that_DT fibrillar_NN fibronectin_NN may_MD stimulate_VB signal_NN
        transduction_NN pathways_NNS in_IN cells_NNS that_WDT are_VBP either_DT not_RB
        stimulated_VBN ,_, or_CC only_RB marginally_RB stimulated_VBN ,_, by_IN dimeric_JJ
        fibronectin_NN ._.
        Fibronectin_NNP matrix_NN assembly_NN is_VBZ a_DT cell-mediated_JJ process_NN
        that_WDT requires_VBZ the_DT activity_NN of_IN integrins_NNS [_NN 1_CD 6_CD 7_CD 8_CD ]_NN ._. The_DT
        integrin_NN that_WDT is_VBZ primarily_RB responsible_JJ for_IN assembling_VBG
        fibronectin_NN into_IN the_DT matrix_NN is_VBZ α_NN 5_CD β_NN 1_CD ,_, although_IN αvβ_NN 3_CD ,_, αllbβ_NN 3_CD
        and_CC α_NN 4_CD β_NN 1_CD can_MD also_RB function_VB in_IN this_DT capacity_NN [_NN 9_CD 10_CD 11_CD 12_CD 13_CD
        14_CD ]_NN ._. In_IN addition_NN to_TO integrins_NNS ,_, fibronectin_NN matrix_NN
        assembly_NN also_RB depends_VBZ on_IN self-association_JJ sites_NNS within_IN
        fibronectin_NN ._. For_IN example_NN ,_, the_DT N-_NNP terminal_NN 70_CD kDa_NN region_NN ,_, the_DT
        1_CD sttype_NN III_NNP repeat_NN and_CC the_DT 10_CD thtype_NN III_NNP repeat_NN are_VBP
        thought_VBN to_TO be_VB important_JJ for_IN the_DT proper_JJ alignment_NN of_IN
        fibronectin_NN molecules_NNS during_IN matrix_NN assembly_NN [_NN 15_CD 16_CD 17_CD 18_CD
        19_CD 20_CD 21_CD 22_CD ]_NN ._. We_PRP and_CC others_NNS have_VBP shown_VBN that_IN a_DT recombinant_JJ
        protein_NN representing_VBG a_DT portion_NN of_IN the_DT first_JJ type_NN III_NNP repeat_NN
        (_( protein_NN III_NNP 1_CD -_: C_NNP )_) can_MD affect_VB fibronectin_NN matrix_NN assembly_NN and_CC
        cell_NN growth_NN [_NN 2_CD 3_CD 4_CD 16_CD ]_NN ._. Moreover_RB ,_, a_DT mutant_JJ recombinant_JJ
        fibronectin_NN molecule_NN that_WDT is_VBZ lacking_VBG the_DT first_JJ seven_CD type_NN
        III_NNP repeats_VBZ has_VBZ been_VBN shown_VBN to_TO lead_VB to_TO defective_JJ fibronectin_NN
        matrix_NN assembly_NN in_IN cell_NN culture_NN and_CC in_IN vivo_NN ,_, and_CC to_TO
        inhibition_NN of_IN cell_NN proliferation_NN [_NN 23_CD 24_CD ]_NN ._. Although_IN the_DT
        matrix_NN produced_VBN with_IN fibronectin_NN lacking_VBG the_DT first_JJ seven_CD
        type_NN III_NNP repeats_VBZ was_VBD somewhat_RB aberrant_NN ,_, this_DT study_NN does_VBZ
        show_NN that_IN some_DT matrix_NN assembly_NN can_MD occur_VB without_IN the_DT first_JJ
        type_NN III_NNP repeat_NN ._. Therefore_RB ,_, several_JJ approaches_NNS reveal_VBP that_IN
        the_DT fibronectin_NN type_NN III_NNP repeats_VBZ ,_, and_CC especially_RB the_DT first_JJ
        type_NN III_NNP repeat_NN ,_, play_VB important_JJ roles_NNS in_IN the_DT regulation_NN of_IN
        fibronectin_NN matrix_NN assembly_NN and_CC cell_NN growth_NN ._.
        III_NNP 1_CD -_: C_NNP is_VBZ known_VBN to_TO inhibit_VB cell_NN proliferation_NN [_NN 3_CD 4_CD ]_NN ._.
        Recently_RB ,_, III_NNP 1_CD -_: C_NNP (_( also_RB known_VBN as_IN anastellin_NN )_) has_VBZ been_VBN shown_VBN
        to_TO inhibit_VB angiogenesis_NNS ,_, and_CC tumor_NN growth_NN and_CC metastasis_NNS [_NN
        25_CD ]_NN ._. In_IN the_DT present_JJ study_NN we_PRP examine_VBP how_WRB cells_NNS interact_NN
        with_IN and_CC respond_VB to_TO III_NNP 1_CD -_: C_NNP ,_, with_IN a_DT particular_JJ focus_NN on_IN
        signaling_VBG through_IN the_DT Ras_NNP /_NN ERK_NNP pathway_NN ._. We_PRP find_VBP that_IN cells_NNS
        can_MD adhere_VB and_CC spread_VB on_IN III_NNP 1_CD -_: C_NNP and_CC that_IN two_CD classes_NNS of_IN
        receptors_NNS function_VBP in_IN cell_NN adhesion_NN to_TO III_NNP 1_CD -_: C_NNP ;_: integrins_NNS
        and_CC cell-surface_JJ proteoglycans_NNS ._.
      
      
        Results_NNS
        
          Cell_NNP attachment_NN and_CC spreading_VBG on_IN the_DT first_JJ type_NN III_NNP
          repeat_NN of_IN fibronectin_NN
          III_NNP 1_CD -_: C_NNP is_VBZ a_DT recombinant_JJ fibronectin_NN fragment_NN that_WDT
          encompasses_VBZ most_JJS of_IN the_DT first_JJ type_NN III_NNP repeat_NN ,_, but_CC is_VBZ
          missing_VBG the_DT A_DT and_CC B_NNP β-strands_JJ of_IN the_DT repeat_NN [_NN 2_CD ]_NN ._. We_PRP
          had_VBD previously_RB found_VBN that_IN III_NNP 1_CD -_: C_NNP inhibited_VBD the_DT growth_NN of_IN
          normal_JJ diploid_NN smooth_JJ muscle_NN cells_NNS (_( SMCs_NNP )_) in_IN culture_NN [_NN 4_CD
          ]_NN ._. During_IN these_DT experiments_NNS we_PRP noticed_VBD that_IN the_DT presence_NN
          of_IN III_NNP 1_CD -_: C_NNP in_IN the_DT culture_NN medium_NN affected_VBD the_DT morphology_NN
          of_IN cells_NNS at_IN early_JJ times_NNS after_IN plating_VBG ._. As_IN shown_VBN in_IN Figure_NN
          1_CD ,_, cells_NNS plated_JJ onto_IN fibronectin_NN coated_JJ dishes_NNS attached_VBN
          and_CC spread_NN well_RB ,_, typically_RB containing_VBG numerous_JJ
          lamellipodia_NN per_IN cell_NN (_( Fig_NNP ._. 1_LS A_DT ,_, panel_NN FN_NNP )_) ._. Cells_NNP seeded_VBN
          onto_IN fibronectin_NN coated_VBN dishes_NNS with_IN III_NNP 1_CD -_: C_NNP in_IN the_DT culture_NN
          medium_NN spread_VBD more_RBR extensively_RB and_CC in_IN a_DT more_RBR circular_JJ
          pattern_NN at_IN early_JJ times_NNS after_IN plating_VBG than_IN cells_NNS plated_JJ on_IN
          fibronectin_NN in_IN the_DT absence_NN of_IN III_NNP 1_CD -_: C_NNP (_( Fig_NNP ._. 1_LS A_DT ,_, panels_NNS FN_NNP
          and_CC FN_NNP +_NN C_NNP ,_, and_CC Fig_NNP ._. 1_LS B_NNP )_) ._. Cells_NNP cultured_JJ on_IN fibronectin_NN for_IN
          4_CD hours_NNS show_VBP approximately_RB the_DT same_JJ extent_NN of_IN spreading_VBG
          as_IN cells_NNS on_IN fibronectin_NN plus_CC III_NNP 1_CD -_: C_NNP (_( Fig_NNP ._. 1_LS B_NNP )_) ,_, indicating_VBG
          that_IN III_NNP 1_CD -_: C_NNP accelerated_VBD the_DT rate_NN of_IN spreading_VBG of_IN the_DT
          cells_NNS but_CC did_VBD not_RB affect_VB the_DT eventual_JJ extent_NN of_IN
          spreading_VBG ._. The_DT effect_NN on_IN cell_NN morphology_NN was_VBD specific_JJ for_IN
          III_NNP 1_CD -_: C_NNP because_IN the_DT negative_JJ control_NN protein_NN III_NNP 11_CD -_: C_NNP (_( a_DT
          recombinant_JJ protein_NN derived_VBN from_IN the_DT 11_CD thtype_NN III_NNP repeat_NN
          in_IN fibronectin_NN ,_, which_WDT ,_, similar_JJ to_TO III_NNP 1_CD -_: C_NNP ,_, is_VBZ missing_VBG the_DT
          A_DT and_CC B_NNP β-strands_JJ of_IN this_DT repeat_NN )_) had_VBD no_DT effect_NN on_IN the_DT
          morphology_NN of_IN the_DT cells_NNS (_( Fig_NNP ._. 1_LS A_DT ,_, panel_NN FN_NNP +_NN 11_CD C_NNP ,_, and_CC Fig_NNP ._.
          1_LS B_NNP )_) ._. Interestingly_RB ,_, the_DT effect_NN of_IN III_NNP 1_CD -_: C_NNP on_IN cell_NN
          morphology_NN was_VBD seen_VBN even_RB when_WRB the_DT plates_NNS had_VBD 
          not_RB been_VBN coated_VBN with_IN fibronectin_NN
          (_( Fig_NNP ._. 1_LS A_DT ,_, panel_NN C_NNP ,_, and_CC Fig_NNP ._. 1_LS B_NNP )_) ,_, indicating_VBG that_IN intact_JJ
          fibronectin_NN was_VBD not_RB required_VBN for_IN cell_NN attachment_NN and_CC
          spreading_VBG when_WRB III_NNP 1_CD -_: C_NNP was_VBD in_IN the_DT culture_NN medium_NN ._. Again_RB ,_,
          the_DT negative_JJ control_NN protein_NN III_NNP 11_CD -_: C_NNP had_VBD no_DT effect_NN on_IN
          cell_NN morphology_NN ;_: cells_NNS seeded_VBN onto_IN uncoated_JJ plates_NNS with_IN
          III_NNP 11_CD -_: C_NNP in_IN the_DT culture_NN medium_NN remained_VBD rounded_JJ and_CC did_VBD
          not_RB appreciably_RB spread_VB over_IN several_JJ hours_NNS (_( Fig_NNP ._. 1_LS A_DT ,_, panel_NN
          11_CD C_NNP ,_, and_CC Fig_NNP ._. 1_LS B_NNP )_) ._. These_DT results_NNS indicated_VBD that_IN III_NNP 1_CD -_: C_NNP
          had_VBD an_DT effect_NN on_IN the_DT morphology_NN of_IN freshly_RB plated_JJ cells_NNS ._.
          Moreover_RB ,_, the_DT plates_NNS did_VBD not_RB need_VB to_TO be_VB coated_VBN with_IN any_DT
          adhesive_NN protein_NN prior_RB to_TO seeding_VBG the_DT cells_NNS with_IN III_NNP 1_CD -_: C_NNP
          in_IN the_DT culture_NN medium_NN ,_, indicating_VBG that_IN III_NNP 1_CD -_: C_NNP may_MD have_VB
          adsorbed_JJ onto_IN the_DT tissue_NN culture_NN plastic_NN and_CC that_IN cells_NNS
          then_RB attached_VBN and_CC spread_NN on_IN the_DT adsorbed_JJ III_NNP 1_CD -_: C_NNP ._.
          To_TO directly_RB test_VB whether_IN cells_NNS were_VBD able_JJ to_TO bind_NN to_TO
          III_NNP 1_CD -_: C_NNP coated_JJ on_IN a_DT dish_NN ,_, various_JJ concentrations_NNS of_IN either_DT
          fibronectin_NN ,_, III_NNP 1_CD -_: C_NNP or_CC III_NNP 11_CD -_: C_NNP were_VBD coated_JJ onto_IN dishes_NNS
          and_CC cell_NN attachment_NN to_TO these_DT substrates_NNS was_VBD measured_VBN ._. As_IN
          shown_VBN in_IN Figure_NN 2_CD ,_, cells_NNS attach_VBP well_RB to_TO fibronectin_NN and_CC
          to_TO III_NNP 1_CD -_: C_NNP ,_, but_CC not_RB to_TO III_NNP 11_CD -_: C_NNP coated_JJ on_IN a_DT dish_NN ._. On_IN a_DT
          molar_NN basis_NN ,_, III_NNP 1_CD -_: C_NNP was_VBD less_RBR effective_JJ at_IN supporting_VBG cell_NN
          attachment_NN than_IN fibronectin_NN ,_, however_RB ,_, it_PRP was_VBD clear_JJ that_IN
          RASMCs_NNP do_VBP attach_VB and_CC spread_VB well_RB on_IN III_NNP 1_CD -_: C_NNP coated_JJ on_IN a_DT
          dish_NN ._. The_DT morphology_NN of_IN the_DT cells_NNS seeded_VBN onto_IN the_DT
          III_NNP 1_CD -_: C-_NNP coated_JJ wells_NNS was_VBD indistinguishable_JJ from_IN the_DT
          morphology_NN shown_VBN in_IN Fig_NNP ._. 1_LS A_DT ,_, panel_NN C_NNP ._.
        
        
          Role_NNP of_IN integrins_NNS in_IN cell_NN attachment_NN to_TO
          III_NNP 1_CD -_: C_NNP
          The_DT attachment_NN of_IN RASMCs_NNP to_TO III_NNP 1_CD -_: C_NNP was_VBD analyzed_VBN
          further_JJ to_TO determine_VB the_DT role_NN played_VBN by_IN integrins_NNS as_IN
          potential_JJ adhesive_NN receptors_NNS for_IN III_NNP 1_CD -_: C_NNP ._. Various_JJ
          integrin-blocking_JJ reagents_NNS were_VBD tested_VBN for_IN their_PRP$ ability_NN
          to_TO block_VB RASMC_NNP attachment_NN to_TO III_NNP 1_CD -_: C_NNP and_CC to_TO fibronectin_NN ._.
          The_DT adhesion_NN of_IN SMCs_NNP to_TO fibronectin_NN is_VBZ mediated_JJ through_IN
          β_NN 1_CD integrins_NNS [_NN 1_CD 26_CD ]_NN ._. We_PRP confirmed_VBD these_DT previous_JJ
          findings_NNS for_IN our_PRP$ RASMCs_NNP ,_, by_IN showing_VBG a_DT complete_JJ block_NN of_IN
          cell_NN attachment_NN to_TO fibronectin_NN by_IN EDTA_NNP (_( an_DT agent_NN that_IN
          blocks_NNS all_DT integrins_NNS )_) ,_, anti-β_JJ 1_CD blocking_VBG mAb_NN ,_, and_CC RGD_NNP
          peptide_NN ,_, but_CC not_RB by_IN the_DT negative_JJ control_NN RAD_NNP peptide_NN
          (_( Fig_NNP ._. 3_LS A_DT )_) ._. Anti-fibronectin_NNP antibodies_NNS also_RB effectively_RB
          blocked_VBN RASMC_NNP attachment_NN to_TO fibronectin_NN (_( Fig_NNP ._. 3_LS A_DT )_) ._.
          Heparin_NNP did_VBD not_RB inhibit_VB cell_NN attachment_NN to_TO fibronectin_NN
          (_( Fig_NNP ._. 3_LS A_DT )_) ,_, however_RB ,_, it_PRP did_VBD modestly_RB reduce_VB cell_NN spreading_VBG
          on_IN fibronectin_NN (_( 15_CD %_NN inhibition_NN of_IN cell_NN spreading_VBG ,_, data_NNS
          not_RB shown_VBN )_) ._. These_DT results_NNS indicate_VBP that_IN RASMC_NNP adhesion_NN to_TO
          fibronectin_NN is_VBZ mediated_JJ by_IN β_NN 1_CD integrins_NNS ._.
          Blocking_NNP studies_NNS indicated_VBD that_DT cell_NN attachment_NN to_TO
          III_NNP 1_CD -_: C_NNP was_VBD partially_RB mediated_JJ by_IN β_NN 1_CD integrins_NNS ._. For_IN
          example_NN ,_, RASMC_NNP attachment_NN was_VBD partially_RB blocked_VBN by_IN EDTA_NNP ,_,
          anti-β_JJ 1_CD mAb_NN ,_, and_CC RGD_NNP peptide_NN (_( Fig_NNP ._. 3_LS B_NNP )_) ,_, indicating_VBG the_DT
          involvement_NN of_IN integrins_NNS ._. However_RB ,_, cell_NN attachment_NN was_VBD
          also_RB partially_RB blocked_VBN by_IN heparin_NN ,_, which_WDT did_VBD not_RB inhibit_VB
          cell_NN attachment_NN to_TO fibronectin_NN (_( Fig_NNP ._. 3_LS Aand_NNP 3_CD B_NNP ,_, Hep_NNP
          samples_NNS )_) ,_, indicating_VBG that_IN a_DT non-integrin_JJ receptor_NN also_RB
          mediated_JJ cell_NN attachment_NN to_TO III_NNP 1_CD -_: C_NNP ._. A_DT complete_JJ block_NN of_IN
          cell_NN attachment_NN to_TO III_NNP 1_CD -_: C_NNP was_VBD only_RB observed_VBN when_WRB heparin_NN
          was_VBD combined_VBN with_IN integrin_NN blocking_VBG agents_NNS ;_: e_SYM ._. g_SYM ._. ,_, heparin_NN
          +_NN anti-β_JJ 1_CD mAb_NN or_CC heparin_NN +_NN RGD_NNP peptide_NN (_( Fig_NNP ._. 3_LS B_NNP )_) ._.
          Anti-fibronectin_NNP antibodies_NNS modestly_RB inhibited_VBD cell_NN
          attachment_NN ,_, but_CC anti-_NN III_NNP 1_CD -_: C_NNP antibodies_NNS effectively_RB
          blocked_VBN cell_NN attachment_NN to_TO III_NNP 1_CD -_: C_NNP (_( Fig_NNP ._. 3_LS B_NNP )_) ._. These_DT
          results_NNS demonstrate_VBP that_DT cell_NN attachment_NN to_TO III_NNP 1_CD -_: C_NNP was_VBD
          mediated_JJ through_IN both_DT β_NN 1_CD integrins_NNS and_CC another_DT class_NN of_IN
          receptors_NNS on_IN RASMCs_NNP ._.
          One_CD way_NN in_IN which_WDT integrins_NNS were_VBD originally_RB shown_VBN to_TO be_VB
          fibronectin_NN receptors_NNS was_VBD by_IN affinity_NN chromatography_NN of_IN
          radioiodinated_JJ cell_NN surface_NN proteins_NNS on_IN a_DT fibronectin_NN
          column_NN [_NN 27_CD 28_CD ]_NN ._. Consistent_NNP with_IN these_DT earlier_JJR studies_NNS ,_,
          cell_NN surface_NN radioiodination_NN of_IN RASMCs_NNP followed_VBN by_IN
          affinity_NN chromatography_NN on_IN fibronectin_NN Sepharose_NNP and_CC
          elution_NN with_IN EDTA_NNP revealed_VBD the_DT binding_JJ of_IN two_CD major_JJ bands_NNS
          at_IN 120_CD kDa_NN and_CC 140_CD kDa_NN (_( Fig_NNP ._. 4_LS ,_, Elane_NNP under_IN FN_NNP )_) ._. These_DT
          sizes_NNS match_VBP those_DT of_IN the_DT β_NN 1_CD and_CC α_NN 5_CD integrin_NN submits_VBZ ,_,
          respectively_RB ,_, that_WDT have_VBP been_VBN shown_VBN by_IN affinity_NN
          chromatography_NN to_TO bind_NN to_TO the_DT cell_NN binding_JJ domain_NN (_( i_NNP ._. e_SYM ._. ,_,
          10_CD thtype_NN III_NNP repeat_NN )_) of_IN fibronectin_NN [_NN 27_CD 28_CD 29_CD 30_CD 31_CD ]_NN ._.
          Affinity_NNP chromatography_NN on_IN a_DT III_NNP 1_CD -_: C_NNP Sepharose_NNP column_NN
          revealed_VBD the_DT binding_JJ of_IN three_CD major_JJ bands_NNS of_IN sizes_NNS 120_CD
          kDa_NN ,_, 140_CD kDa_NN and_CC 150_CD kDa_NN (_( Fig_NNP ._. 4_LS ,_, Elane_NNP under_IN C_NNP )_) ._. The_DT 120_CD
          kDa_NN and_CC 140_CD kDa_NN bands_NNS likely_JJ represent_VB the_DT β_NN 1_CD and_CC α_NN 5_CD
          subunits_NNS (_( as_IN above_IN )_) ,_, while_IN the_DT 150_CD kDa_NN band_NN may_MD represent_VB
          either_CC the_DT α_NN 2_CD or_CC α_NN 3_CD integrin_NN subunits_NNS ,_, which_WDT are_VBP known_VBN to_TO
          be_VB expressed_VBN by_IN VSMCs_NNP [_NN 26_CD ]_NN ._. Affinity_NNP chromatography_NN on_IN
          the_DT control_JJ III_NNP 11_CD -_: C_NNP column_NN yielded_VBD no_DT radioiodinated_JJ
          proteins_NNS that_WDT were_VBD eluted_JJ from_IN the_DT column_NN (_( Fig_NNP ._. 4_LS ,_, Elane_NNP
          under_IN 11_CD C_NNP )_) ._. These_DT results_NNS are_VBP consistent_JJ with_IN the_DT
          hypothesis_NNS that_IN one_CD or_CC more_JJR pi_NN integrins_NNS act_VBP as_IN receptors_NNS
          for_IN III_NNP 1_CD -_: C_NNP ._. Taken_VBN together_RB with_IN the_DT integrin-blocking_JJ
          results_NNS described_VBD above_IN ,_, it_PRP is_VBZ clear_JJ that_IN RASMC_NNP adhesion_NN
          to_TO III_NNP 1_CD -_: C_NNP is_VBZ partially_RB mediated_JJ through_IN β_NN 1_CD integrins_NNS ._.
        
        
          Cell_NNP adhesion_NN to_TO III_NNP 1_CD -_: C_NNP activates_NNS ERK_NNP 1_CD /_NN 2_CD
          Integrins_NNP are_VBP known_VBN to_TO activate_VBP signaling_VBG pathways_NNS in_IN
          cells_NNS [_NN 32_CD 33_CD 34_CD 35_CD ]_NN ._. Among_IN the_DT most_RBS well-studied_JJ
          signaling_VBG pathways_NNS is_VBZ the_DT Ras_NNP /_NN MAPK_NNP pathway_NN leading_VBG to_TO
          activation_NN of_IN ERK_NNP 1_CD and_CC ERK_NNP 2_CD [_NN 36_CD ]_NN ._. We_PRP therefore_RB decided_VBD
          to_TO test_VB the_DT effect_NN of_IN cell_NN adhesion_NN to_TO III_NNP 1_CD -_: C_NNP on_IN ERK_NNP
          activation_NN ._. As_IN expected_VBN ,_, treatment_NN of_IN RASMCs_NNP with_IN PDGF_NNP
          resulted_VBD in_IN activation_NN of_IN ERK_NNP 1_CD /_NN 2_CD (_( Fig_NNP ._. 5_LS ,_, PDGF_NNP lanes_NNS )_) ._.
          Plating_NNP RASMCs_NNP onto_IN a_DT fibronectin_NN coated_JJ dish_NN in_IN the_DT
          absence_NN of_IN growth_NN factors_NNS yielded_VBD moderate_JJ activation_NN of_IN
          ERK_NNP 1_CD /_NN 2_CD ,_, which_WDT peaked_VBD at_IN 30_CD min_NN then_RB decreased_VBD somewhat_RB
          over_IN the_DT next_JJ 30_CD min_NN of_IN the_DT experiment_NN (_( Fig_NNP ._. 5_LS ,_, bottom_JJ
          panel_NN )_) ._. However_RB ,_, plating_VBG cells_NNS onto_IN a_DT III_NNP 1_CD -_: C_NNP coated_JJ dish_NN
          gave_VBD strong_JJ activation_NN of_IN ERK_NNP 1_CD /_NN 2_CD ,_, which_WDT peaked_VBD at_IN 30_CD min_NN
          and_CC remained_VBD relatively_RB constant_JJ for_IN the_DT subsequent_JJ 30_CD
          min_NN (_( Fig_NNP ._. 5_LS ,_, top_JJ panel_NN )_) ._. The_DT control_NN protein_NN III_NNP 11_CD -_: C_NNP did_VBD
          not_RB appreciably_RB stimulate_VB ERK_NNP 1_CD /_NN 2_CD phosphorylation_NN (_( Fig_NNP ._. 5_LS ,_,
          11_CD C_NNP lanes_NNS ,_, both_DT panels_NNS )_) ._. Thus_RB ,_, the_DT adhesion_NN of_IN RASMCs_NNP to_TO
          III_NNP 1_CD -_: C_NNP resulted_VBD in_IN robust_JJ activation_NN of_IN ERK_NNP 1_CD /_NN 2_CD that_WDT was_VBD
          comparable_JJ to_TO the_DT activation_NN obtained_VBN with_IN PDGF_NNP ._.
        
        
          ERK_NNP activation_NN by_IN III_NNP 1_CD -_: C_NNP is_VBZ dependent_JJ on_IN β_NN 1_CD
          integrins_NNS
          As_IN shown_VBN above_IN ,_, several_JJ agents_NNS that_WDT block_VBP β_NN 1_CD integrin_NN
          function_NN partially_RB inhibit_VB cell_NN attachment_NN to_TO III_NNP 1_CD -_: C_NNP ._. We_PRP
          therefore_RB tested_VBD the_DT effects_NNS of_IN these_DT agents_NNS on_IN ERK_NNP 1_CD /_NN 2_CD
          activation_NN by_IN III_NNP 1_CD -_: C_NNP ._. The_DT results_NNS obtained_VBN with_IN ERK_NNP 1_CD /_NN 2_CD
          activation_NN closely_RB paralleled_JJ the_DT results_NNS obtained_VBN with_IN
          cell_NN attachment_NN to_TO III_NNP 1_CD -_: C_NNP ,_, except_IN that_IN the_DT individual_JJ
          blocking_VBG agents_NNS were_VBD relatively_RB more_RBR efficient_JJ at_IN
          inhibiting_VBG ERK_NNP 1_CD /_NN 2_CD activation_NN ._. For_IN example_NN ,_, heparin_NN ,_, EDTA_NNP ,_,
          anti-β_JJ 1_CD mAb_NN and_CC RGD_NNP peptide_NN all_DT significantly_RB inhibited_VBD
          ERK_NNP 1_CD /_NN 2_CD activation_NN by_IN cell_NN adhesion_NN to_TO III_NNP 1_CD -_: C_NNP (_( Fig_NNP ._. 6_CD )_) ._.
          Heparin_NNP was_VBD most_RBS effective_JJ and_CC completely_RB blocked_VBN ERK_NNP 1_CD /_NN 2_CD
          activation_NN ._. (_( Fig_NNP ._. 6_CD )_) ._. In_IN contrast_NN ,_, the_DT negative_JJ control_NN
          RAD_NNP peptide_NN did_VBD not_RB inhibit_VB ERK_NNP 1_CD /_NN 2_CD activation_NN by_IN III_NNP 1_CD -_: C_NNP
          (_( Fig_NNP ._. 6_CD ,_, C_NNP +_NN RAD_NNP lane_NN )_) ._. These_DT results_NNS indicate_VBP that_IN both_DT
          integrins_NNS and_CC the_DT class_NN of_IN receptors_NNS inhibited_VBD by_IN heparin_NN
          were_VBD required_VBN for_IN III_NNP 1_CD -_: C_NNP mediated_JJ activation_NN of_IN
          ERK_NNP 1_CD /_NN 2_CD ._.
        
        
          Role_NNP of_IN heparan_NN sulfate_NN proteoglycans_NNS in_IN cell_NN
          adhesion_NN to_TO III_NNP 1_CD -_: C_NNP and_CC ERK_NNP 1_CD /_NN 2_CD activation_NN by_IN III_NNP 1_CD -_: C_NNP
          Because_IN heparin_NN was_VBD able_JJ to_TO inhibit_VB the_DT attachment_NN of_IN
          cells_NNS to_TO III_NNP 1_CD -_: C_NNP and_CC the_DT activation_NN of_IN ERK_NNP 1_CD /_NN 2_CD by_IN III_NNP 1_CD -_: C_NNP ,_,
          we_PRP tested_VBD the_DT effect_NN of_IN other_JJ glycosaminoglycans_NNS on_IN
          III_NNP 1_CD -_: C_NNP stimulated_VBN ERK_NNP 1_CD /_NN 2_CD activity_NN ._. Heparin_NNP ,_, heparan_NN
          sulfate_NN and_CC dermatan_NN sulfate_NN blocked_VBD ERK_NNP 1_CD /_NN 2_CD activation_NN by_IN
          III_NNP 1_CD -_: C_NNP (_( Fig_NNP ._. 7_CD )_) ,_, and_CC cell_NN adhesion_NN to_TO III_NNP 1_CD -_: C_NNP (_( not_RB shown_VBN )_) ._.
          In_IN contrast_NN ,_, hyaluronic_JJ acid_NN ,_, chondroitin-_NN 4_CD -_: sulfate_NN and_CC
          chondroitin-_NN 6_CD -_: sulfate_NN had_VBD no_DT effect_NN on_IN the_DT ability_NN of_IN
          III_NNP 1_CD -_: C_NNP to_TO stimulate_VB ERK_NNP 1_CD /_NN 2_CD activity_NN (_( Fig_NNP ._. 7_CD )_) or_CC on_IN the_DT
          adhesion_NN of_IN cells_NNS to_TO III_NNP 1_CD -_: C_NNP (_( not_RB shown_VBN )_) ._. It_PRP is_VBZ possible_JJ
          that_DT heparin_NN ,_, heparan_NN sulfate_NN and_CC dermatan_NN sulfate_NN
          inhibit_VB III_NNP 1_CD -_: C_NNP mediated_JJ cell_NN adhesion_NN and_CC ERK_NNP 1_CD /_NN 2_CD
          activation_NN due_JJ to_TO common_JJ chemical_NN features_NNS ._. For_IN example_NN ,_,
          heparin_NN ,_, heparan_NN sulfate_NN ,_, and_CC dermatan_NN sulfate_NN all_DT
          contain_VBP iduronic_JJ acid_NN residues_NNS whereas_IN chondroitin_NN
          sulfate_NN and_CC hyaluronic_JJ acid_NN do_VBP not_RB ._. The_DT results_NNS presented_VBN
          above_IN indicate_VBP that_IN a_DT heparan_NN sulfate_NN proteoglycan_NN (_( HSPG_NNP )_)
          or_CC dermatan_NN sulfate_NN proteoglycan_NN on_IN the_DT surface_NN of_IN RASMCs_NNP
          may_MD serve_VB as_IN a_DT receptor_NN for_IN III_NNP 1_CD -_: C_NNP ._.
          To_TO further_VB explore_VB the_DT possibility_NN that_IN a_DT cell_NN surface_NN
          proteoglycan_NN serves_VBZ as_IN a_DT receptor_NN for_IN III_NNP 1_CD -_: C_NNP ,_, RASMCs_NNP were_VBD
          treated_VBN with_IN the_DT glycosaminoglycan-degrading_JJ enzymes_NNS
          seeded_VBN onto_IN III_NNP 1_CD -_: C_NNP ,_, and_CC analyzed_VBD for_IN the_DT activation_NN of_IN
          ERK_NNP 1_CD /_NN 2_CD ._. Heparitinase_NNP treatment_NN ,_, but_CC not_RB chondroitinase_NN
          ABC_NNP treatment_NN decreased_VBD the_DT amount_NN of_IN ERK_NNP 1_CD /_NN 2_CD activation_NN
          by_IN III_NNP 1_CD -_: C_NNP (_( Fig_NNP ._. 8_CD )_) ._. Heparitinase_NNP treatment_NN also_RB inhibited_VBD
          cell_NN adhesion_NN by_IN 25_CD -_: 40_CD %_NN ,_, while_IN chondroitinase_NN ABC_NNP
          treatment_NN did_VBD not_RB inhibit_VB cell_NN adhesion_NN to_TO III_NNP 1_CD -_: C_NNP (_( not_RB
          shown_VBN )_) ._. This_DT result_NN is_VBZ consistent_JJ with_IN the_DT idea_NN that_IN
          HSPGs_NNP but_CC not_RB chondroitin_NN sulfate_NN proteoglycans_NNS serve_VBP as_IN
          signaling_VBG receptors_NNS for_IN III_NNP 1_CD -_: C_NNP ._.
          To_TO identify_VB the_DT cell_NN surface_NN proteoglycans_NNS that_WDT may_MD
          serve_VB as_IN receptors_NNS for_IN III_NNP 1_CD -_: C_NNP ,_, RASMCs_NNP were_VBD labeled_VBN with_IN
          35_CD SO_NNP 
          4_CD and_CC cell_NN lysates_NNS were_VBD applied_VBN to_TO
          III_NNP 1_CD -_: C_NNP and_CC III_NNP 11_CD -_: C_NNP columns_NNS ._. The_DT most_RBS highly_RB labeled_VBN
          band_NN ,_, migrating_VBG in_IN a_DT smear_NN at_IN about_IN 450_CD kDa_NN ,_, bound_VBN
          efficiently_RB to_TO the_DT III_NNP 1_CD -_: C_NNP column_NN (_( Fig_NNP ._. 9_CD A_DT ,_, compare_VB flow_NN
          through_IN and_CC elution_NN lanes_NNS )_) ._. This_DT proteoglycan_NN resisted_VBD
          elution_NN by_IN 8_CD M_NNP urea_NN but_CC was_VBD eluted_JJ by_IN boiling_VBG the_DT
          Sepharose_NNP beads_NNS in_IN SDS_NNP (_( Fig_NNP ._. 9_CD A_DT )_) ._. This_DT same_JJ proteoglycan_NN
          did_VBD not_RB bind_NN appreciably_RB to_TO the_DT III_NNP 11_CD -_: C_NNP column_NN (_( Fig_NNP ._.
          9_CD A_DT )_) ._. Heparitinase_NNP and_CC chondroitinase_NN ABC_NNP treatment_NN of_IN the_DT
          35_CD SO_NNP 
          4_CD labeled_VBN samples_NNS revealed_VBD that_IN the_DT
          450_CD kDa_NN proteoglycan_NN was_VBD composed_VBN mostly_RB of_IN HSPGs_NNP (_( Fig_NNP ._.
          9_CD B_NNP )_) ._. These_DT results_NNS indicate_VBP that_IN most_JJS of_IN the_DT cell_NN surface_NN
          HSPGs_NNP of_IN RASMCs_NNP can_MD bind_NN to_TO III_NNP 1_CD -_: C_NNP in_IN affinity_NN
          chromatography_NN ._.
          RASMC_NNP HSPGs_NNP were_VBD analyzed_VBN further_RB by_IN immunoblotting_VBG
          with_IN the_DT monoclonal_NN antibody_NN 3_CD G_NNP 10_CD which_WDT specifically_RB
          recognizes_VBZ desaturated_JJ uronates_NNS on_IN the_DT heparan_NN sulfate_NN
          stubs_NNS that_WDT remain_VBP associated_VBN with_IN core_NN proteins_NNS after_IN
          heparitinase_NN digestion_NN [_NN 37_CD ]_NN ._. Complete_JJ digestion_NN of_IN
          RASMC_NNP lysates_NNS with_IN heparitinase_NN reveals_VBZ major_JJ bands_NNS at_IN 46_CD
          kDa_NN and_CC 70_CD kDa_NN ,_, indicating_VBG that_IN these_DT are_VBP the_DT sizes_NNS of_IN
          the_DT major_JJ HSPG_NNP core_NN proteins_NNS (_( not_RB shown_VBN )_) ._. RASMC_NNP lysates_NNS
          were_VBD subjected_VBN to_TO partial_JJ heparitinase_NN treatment_NN (_( full_JJ
          digestion_NN was_VBD not_RB performed_VBN in_IN order_NN to_TO allow_VB some_DT GAGs_NNP
          to_TO remain_VB associated_VBN with_IN the_DT core_NN proteins_NNS )_) then_RB applied_VBN
          to_TO either_CC III_NNP 1_CD -_: C_NNP or_CC III_NNP 11_CD -_: C_NNP Sepharose_NNP ._. As_IN shown_VBN in_IN Fig_NNP ._.
          10_CD ,_, most_JJS of_IN the_DT 46_CD kDa_NN and_CC 70_CD kDa_NN HSPGs_NNP bound_VBN to_TO III_NNP 1_CD -_: C_NNP
          Sepharose_NNP but_CC not_RB to_TO III_NNP 11_CD -_: C_NNP Sepharose_NNP ._. In_IN addition_NN ,_, the_DT
          presence_NN of_IN heparin_NN in_IN the_DT lysate_NN inhibited_VBD the_DT 46_CD kDa_NN
          and_CC 70_CD kDa_NN HSPGs_NNP from_IN binding_VBG to_TO the_DT III_NNP 1_CD -_: C_NNP column_NN (_( Fig_NNP ._.
          10_CD ,_, compare_VBP C_NNP and_CC C_NNP •_NN H_NNP lanes_NNS )_) ._. The_DT inhibition_NN of_IN 46_CD kDa_NN
          and_CC 70_CD kDa_NN binding_JJ to_TO III_NNP 1_CD -_: C_NNP by_IN heparin_NN suggests_VBZ that_IN
          these_DT HSPGs_NNP may_MD serve_VB as_IN receptors_NNS for_IN III_NNP 1_CD -_: C_NNP in_IN cell_NN
          adhesion_NN and_CC ERK_NNP 1_CD /_NN 2_CD signaling_VBG ._.
        
      
      
        Discussion_NNP
        We_PRP have_VBP found_VBN that_IN cells_NNS can_MD interact_NN with_IN a_DT portion_NN of_IN
        the_DT fibronectin_NN first_RB type_NN III_NNP repeat_NN ,_, leading_VBG to_TO cell_NN
        adhesion_NN and_CC activation_NN of_IN ERK_NNP ,_, and_CC that_IN this_DT signaling_VBG
        requires_VBZ both_DT cell_NN surface_NN HSPGs_NNP and_CC integrins_NNS ._. RASMCs_NNP are_VBP
        able_JJ to_TO adhere_VB to_TO and_CC spread_NN on_IN III_NNP 1_CD -_: C_NNP ._. Adhesion_NNP to_TO III_NNP 1_CD -_: C_NNP
        results_NNS in_IN robust_JJ activation_NN of_IN ERK_NNP ;_: comparable_JJ to_TO that_DT
        seen_VBN with_IN PDGF_NNP stimulation_NN ._. Several_JJ independent_JJ lines_NNS of_IN
        evidence_NN indicate_VBP that_DT cell_NN surface_NN HSPGs_NNP and_CC β_NN 1_CD integrins_NNS
        act_VBP as_IN receptors_NNS for_IN III_NNP 1_CD -_: C_NNP and_CC are_VBP required_VBN for_IN cell_NN
        adhesion_NN and_CC ERK_NNP activation_NN by_IN III_NNP 1_CD -_: C_NNP ._. For_IN example_NN ,_, various_JJ
        β_NN 1_CD integrin_NN blocking_VBG agents_NNS inhibit_VBP cell_NN attachment_NN to_TO
        III_NNP 1_CD -_: C_NNP and_CC ERK_NNP activation_NN by_IN III_NNP 1_CD -_: C_NNP ._. In_IN addition_NN ,_,
        inhibition_NN by_IN heparin_NN ,_, heparan-sulfate_JJ ,_, and_CC heparitinase_NN ,_,
        but_CC not_RB by_IN chondroitin_NN sulfates_NNS or_CC chondroitinase_NN ABC_NNP all_DT
        point_NN to_TO the_DT importance_NN of_IN HSPGs_NNP as_IN receptors_NNS ._. Affinity_NNP
        chromatography_NN with_IN 125_CD I_PRP surface_VBP labeled_VBD proteins_NNS resulted_VBD
        in_IN the_DT binding_JJ of_IN proteins_NNS of_IN the_DT appropriate_JJ sizes_NNS of_IN β_NN 1_CD
        integrins_NNS to_TO both_DT FN_NNP and_CC III_NNP 1_CD -_: C_NNP columns_NNS ._. Moreover_RB ,_, affinity_NN
        chromatography_NN with_IN 35_CD SO_NNP 
        4_CD -_: labeled_VBN cells_NNS suggests_VBZ that_IN HSPGs_NNP
        with_IN core_NN protein_NN sizes_NNS of_IN 46_CD kDa_NN and_CC 70_CD kDa_NN serve_VB as_IN
        III_NNP 1_CD -_: C_NNP receptors_NNS ._. Taken_VBN together_RB ,_, these_DT results_NNS indicate_VBP
        that_IN the_DT first_JJ type_NN III_NNP repeat_NN of_IN fibronectin_NN can_MD serve_VB as_IN
        a_DT cell_NN binding_JJ domain_NN and_CC that_IN both_DT integrins_NNS and_CC cell_NN
        surface_NN HSPGs_NNP function_NN as_IN receptors_NNS for_IN this_DT type_NN III_NNP
        repeat_NN ._.
        Our_PRP$ results_NNS demonstrate_VBP that_IN both_DT integrins_NNS and_CC cell_NN
        surface_NN HSPGs_NNP are_VBP required_VBN for_IN robust_JJ ERK_NNP 1_CD /_NN 2_CD activation_NN
        when_WRB cells_NNS adhere_VB to_TO III_NNP 1_CD -_: C_NNP ._. These_DT results_NNS are_VBP one_CD of_IN the_DT
        first_JJ demonstrations_NNS that_IN HSPGs_NNP can_MD activate_VBP the_DT ERK_NNP
        signaling_VBG pathway_NN ._. Another_DT example_NN of_IN this_DT closely_RB
        parallels_VBZ our_PRP$ findings_NNS [_NN 38_CD ]_NN ._. The_DT adhesion_NN of_IN Jurkat_NNP T_NN
        cells_NNS to_TO thrombospondin-_NN 1_CD has_VBZ been_VBN shown_VBN to_TO require_VB the_DT
        cooperation_NN of_IN three_CD classes_NNS of_IN receptors_NNS ;_: β_NN 1_CD integrins_NNS ,_,
        CD_NNP 47_CD and_CC HSPGs_NNP [_NN 38_CD ]_NN ._. Adhesion_NNP of_IN the_DT Jurkat_NNP T_NN cells_NNS to_TO
        thrombospondin-_NN 1_CD stimulates_NNS ERK_NNP 1_CD /_NN 2_CD activation_NN and_CC the_DT
        binding_JJ of_IN HSPGs_NNP to_TO thrombospondin-_NN 1_CD is_VBZ required_VBN for_IN this_DT
        signaling_VBG ._. The_DT particular_JJ HSPGs_NNP that_WDT mediate_VB ERK_NNP 1_CD /_NN 2_CD
        activation_NN in_IN Jurkat_NNP T_NN cells_NNS have_VBP not_RB been_VBN identified_VBN ,_,
        however_RB ,_, the_DT authors_NNS speculate_VBP that_IN syndecans_NNS may_MD
        participate_VB in_IN the_DT adhesion_NN and_CC signaling_VBG in_IN that_DT system_NN [_NN
        38_CD ]_NN ._. This_DT may_MD also_RB be_VB the_DT case_NN in_IN our_PRP$ system_NN ,_, as_IN
        described_VBN below_IN ._.
        One_CD major_JJ family_NN of_IN cell_NN surface_NN HSPGs_NNP is_VBZ the_DT syndecan_NN
        family_NN ._. There_EX are_VBP 4_CD members_NNS in_IN the_DT syndecan_NN family_NN
        (_( syndecan-_NN 1_CD through-_NN 4_LS )_) [_NN 39_CD 40_CD ]_NN ._. Syndecan-_NNP 1_CD ,_, -_: 2_CD and_CC -_: 4_CD
        are_VBP known_VBN to_TO bind_NN to_TO extracellular_NN matrix_NN proteins_NNS and_CC
        syndecan-_NN 1_CD and_CC -_: 4_CD have_VBP been_VBN shown_VBN to_TO support_VB stress_NN fiber_NN
        formation_NN in_IN conjunction_NN with_IN integrins_NNS [_NN 41_CD 42_CD 43_CD 44_CD 45_CD ]_NN
        ._. The_DT HSPGs_NNP we_PRP have_VBP identified_VBN as_IN III_NNP 1_CD -_: C_NNP receptors_NNS have_VBP
        core_NN proteins_NNS that_WDT migrate_VB at_IN the_DT approximate_JJ sizes_NNS of_IN
        syndecan-_NN 1_CD (_( ~_NN 69_CD kDa_NN core_NN protein_NN )_) and_CC syndecan-_NN 2_CD (_( ~_NN 48_CD kDa_NN
        core_NN protein_NN )_) [_NN 40_CD ]_NN ._. It_PRP is_VBZ therefore_RB possible_JJ that_IN our_PRP$ 46_CD
        kDa_NN and_CC 70_CD kDa_NN HSPGs_NNP represent_VB syndecan_NN family_NN members_NNS ._. As_IN
        described_VBD above_IN ,_, the_DT syndecans_NNS may_MD cooperate_VB with_IN β_NN 1_CD
        integrins_NNS and_CC CD_NNP 47_CD to_TO activate_VBP the_DT ERK_NNP signaling_VBG pathway_NN in_IN
        T_NN cells_NNS [_NN 38_CD ]_NN ._. A_DT similar_JJ mechanism_NN may_MD apply_VB to_TO the_DT
        adhesion_NN of_IN RASMCs_NNP to_TO III_NNP 1_CD -_: C_NNP ._. Future_JJ studies_NNS will_MD determine_VB
        the_DT identity_NN of_IN the_DT HSPGs_NNP that_DT act_NN as_IN III_NNP 1_CD -_: C_NNP receptors_NNS ._.
        The_DT Ras_NNP /_NN MAPK_NNP pathway_NN is_VBZ typically_RB thought_VBN to_TO be_VB a_DT part_NN
        of_IN a_DT mitogenic_JJ pathway_NN [_NN 36_CD ]_NN ._. However_RB ,_, we_PRP and_CC others_NNS have_VBP
        shown_VBN that_IN prolonged_VBN treatment_NN with_IN III_NNP 1_CD -_: C_NNP can_MD inhibit_VB cell_NN
        proliferation_NN [_NN 3_CD 4_CD ]_NN ,_, and_CC here_RB we_PRP show_VBP that_DT cell_NN adhesion_NN
        to_TO III_NNP 1_CD -_: C_NNP can_MD activate_VBP ERK_NNP 1_CD /_NN 2_CD ._. One_CD possible_JJ explanation_NN for_IN
        this_DT apparent_JJ discrepancy_NN is_VBZ that_IN although_IN ERK_NNP 1_CD /_NN 2_CD are_VBP often_RB
        involved_VBN in_IN mitogenesis_NNS ,_, in_IN SMCs_NNP ERK_NNP activation_NN can_MD lead_VB to_TO
        inhibition_NN of_IN proliferation_NN [_NN 46_CD ]_NN ._. This_DT occurs_VBZ through_IN
        ERK-mediated_NNP stimulation_NN of_IN PGE_NNP 
        2_CD production_NN ,_, which_WDT then_RB inhibits_NNS the_DT
        proliferation_NN of_IN SMCs_NNP [_NN 46_CD ]_NN ._. Further_RB experiments_NNS will_MD
        determine_VB whether_IN RASMCs_NNP produce_VB PGE_NNP 
        2_CD after_IN treatment_NN with_IN III_NNP 1_CD -_: C_NNP ._. Another_DT
        possibility_NN is_VBZ that_IN III_NNP 1_CD -_: C_NNP stimulates_NNS other_JJ signaling_VBG
        pathways_NNS apart_RB from_IN the_DT ERK_NNP pathway_NN ,_, and_CC that_IN one_CD of_IN the_DT
        other_JJ signaling_VBG pathways_NNS inhibits_NNS proliferation_NN of_IN the_DT
        cells_NNS ._. The_DT relationship_NN between_IN ERK_NNP activation_NN ,_, stimulation_NN
        of_IN other_JJ signaling_VBG pathways_NNS and_CC growth_NN inhibition_NN by_IN III_NNP 1_CD -_: C_NNP
        will_MD be_VB elucidated_JJ by_IN future_JJ experiments_NNS ._.
        The_DT III_NNP 1_CD -_: C_NNP protein_NN has_VBZ recently_RB been_VBN shown_VBN to_TO inhibit_VB
        angiogenesis_NNS ,_, tumor_NN growth_NN and_CC metastasis_NNS [_NN 25_CD ]_NN ._. Those_DT
        findings_NNS ,_, along_IN with_IN our_PRP$ present_JJ findings_NNS reveal_VBP some_DT
        intriguing_JJ parallels_NNS between_IN III_NNP 1_CD -_: C_NNP and_CC the_DT angiogenesis_NNS
        inhibitor_NN endostatin_NN [_NN 47_CD ]_NN ._. For_IN example_NN ,_, both_DT III_NNP 1_CD -_: C_NNP and_CC
        endostatin_NN are_VBP fragments_NNS of_IN matrix_NN proteins_NNS and_CC can_MD inhibit_VB
        angiogenesis_NNS and_CC tumor_NN growth_NN ._. In_IN addition_NN ,_, recent_JJ work_NN has_VBZ
        shown_VBN that_IN cells_NNS interact_NN with_IN endostatin_NN through_IN two_CD
        classes_NNS of_IN receptors_NNS ;_: integrins_NNS and_CC glypicans_NNS (_( cell_NN surface_NN
        HSPGs_NNP )_) [_NN 48_CD 49_CD ]_NN ._. This_DT parallels_VBZ our_PRP$ findings_NNS in_IN this_DT
        present_JJ report_NN ,_, that_IN cells_NNS interact_NN with_IN III_NNP 1_CD -_: C_NNP through_IN
        integrins_NNS and_CC cell_NN surface_NN HSPGs_NNP ._. Therefore_RB ,_, III_NNP 1_CD -_: C_NNP and_CC
        endostatin_NN may_MD inhibit_VB angiogenesis_NNS through_IN related_VBN
        mechanisms_NNS involving_VBG both_DT integrins_NNS and_CC HSPGs_NNP ._. Future_JJ work_NN
        will_MD determine_VB the_DT relative_JJ contributions_NNS of_IN these_DT two_CD
        classes_NNS of_IN receptors_NNS in_IN the_DT biological_JJ effects_NNS of_IN
        III_NNP 1_CD -_: C_NNP ._.
      
      
        Conclusions_NNP
        We_PRP have_VBP found_VBN that_IN cells_NNS can_MD interact_NN with_IN the_DT
        fibronectin_NN first_RB type_NN III_NNP repeat_NN ,_, leading_VBG to_TO cell_NN adhesion_NN
        and_CC activation_NN of_IN ERK_NNP ,_, and_CC that_IN this_DT signaling_VBG requires_VBZ
        both_DT cell_NN surface_NN HSPGs_NNP and_CC integrins_NNS ._. Results_NNS from_IN various_JJ
        independent_JJ types_NNS of_IN experiments_NNS indicate_VBP that_IN the_DT first_JJ
        type_NN III_NNP repeat_NN of_IN fibronectin_NN can_MD serve_VB as_IN a_DT cell_NN binding_JJ
        domain_NN and_CC that_IN both_DT integrins_NNS and_CC cell_NN surface_NN HSPGs_NNP
        function_NN as_IN receptors_NNS for_IN this_DT type_NN III_NNP repeat_NN ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Materials_NNS
          DMEM_NNP and_CC glutamine_NN Pen-_NNP Strep_NNP were_VBD obtained_VBN from_IN Life_NNP
          Technologies_NNPS ,_, Inc_NNP ._. FBS_NNP was_VBD purchased_VBN from_IN HyClone_NNP
          Laboratories_NNPS ,_, Inc_NNP ._. Plasma_NNP fibronectin_NN was_VBD purified_JJ from_IN
          human_JJ plasma_NN by_IN gelatin-agarose_JJ affinity_NN chromatography_NN [_NN
          50_CD ]_NN ._. 4_CD -_: 20_CD %_NN gradient_NN SDS-PAGE_NNP gels_NNS were_VBD from_IN Novex_NNP ._.
          Anti-phospho-p_NNP 44_CD /_NN 42_CD MAPK_NNP polyclonal_NN antibody_NN and_CC
          anti-p_JJ 44_CD /_NN 42_CD ERK_NNP polyclonal_NN antibody_NN were_VBD purchased_VBN from_IN
          New_NNP England_NNP Biolabs_NNP ._. Anti-β_NNP 1_CD blocking_VBG antibody_NN (_( Ha_NNP 2_CD /_NN 5_LS )_)
          was_VBD from_IN PharMingen_NNP ._. Peptides_NNP GRGDSP_NNP and_CC GRADSP_NNP were_VBD
          purchased_VBN from_IN Life_NNP Technologies_NNPS ,_, Inc_NNP ._. Texas_NNP red_JJ and_CC FITC_NNP
          labeled_VBD secondary_JJ antibodies_NNS and_CC 35_CD SO_NNP 
          4_CD were_VBD from_IN ICN_NNP ._. Heparitinase_NNP ,_,
          chondroitinase_NN ABC_NNP and_CC mAb_NN 3_CD G_NNP 10_CD were_VBD from_IN Seikagaku_NNP ._.
          Anti-_NNP FN_NNP antibodies_NNS were_VBD a_DT gift_NN of_IN Dr_NNP ._. Erkki_NNP Ruoslahti_NNP
          (_( Burnham_NNP Institute_NNP )_) ._. ECL_NNP plus_CC reagent_NN and_CC Hyperfilm_NNP were_VBD
          obtained_VBN from_IN Amersham_NNP ._. Complete_JJ ™_NN protease_NN inhibitor_NN
          cocktail_NN tablets_NNS were_VBD purchased_VBN from_IN Boehringer_NNP Mannheim_NNP
          Biochemicals_NNP ._. The_DT expression_NN vector_NN pQE-_NN 12_CD was_VBD obtained_VBN
          from_IN Qiagen_NNP ._. Heparin_NNP and_CC all_DT other_JJ chemicals_NNS were_VBD
          obtained_VBN from_IN Sigma_NNP ._.
          The_DT purified_JJ glycosaminoglycans_NNS used_VBN in_IN this_DT study_NN
          were_VBD a_DT generous_JJ gift_NN of_IN Dr_NNP ._. Nancy_NNP Schwartz_NNP (_( Univ_NNP ._. of_IN
          Chicago_NNP )_) ._. The_DT glycosaminoglycans_NNS were_VBD produced_VBN under_IN a_DT
          contract_NN from_IN the_DT National_NNP Institute_NNP of_IN Arthritis_NNP and_CC
          Musculoskeletal_NNP and_CC Skin_NNP Diseases_NNP (_( NIH_NNP )_) and_CC serve_VB as_IN
          reference_NN standards_NNS ._. The_DT tissue_NN sources_NNS of_IN the_DT
          glycosaminoglycans_NNS were_VBD as_IN follows_VBZ :_: hyaluronic_JJ acid_NN ,_,
          human_JJ umbilical_JJ cord_NN ;_: heparan_NN sulfate_NN ,_, beef_NN lung_NN ;_:
          dermatan_NN sulfate_NN ,_, hog_NN mucosa_NN ;_: chondroitin-_NN 4_CD -_: sulfate_NN ,_,
          notochord_NN from_IN river_NN sturgeon_NN (_( S_NNP ._. platorhynchus_JJ )_) ,_, and_CC
          chondroitin-_NN 6_CD -_: sulfate_NN ,_, cranial_NN cartilage_NN of_IN river_NN
          sturgeon_NN ._.
        
        
          Cell_NNP culture_NN
          Primary_JJ rat_NN aortic_JJ smooth_JJ muscle_NN cells_NNS (_( RASMCs_NNP )_) were_VBD
          isolated_VBN from_IN 12_CD -_: 16_CD week_NN old_JJ Sprague-_NNP Dawley_NNP rats_NNS as_IN
          described_VBN previously_RB [_NN 51_CD ]_NN ._. RASMCs_NNP were_VBD cultured_JJ in_IN
          DMEM_NNP supplemented_JJ with_IN 10_CD %_NN FBS_NNP and_CC glutamine_NN Pen-_NNP Strep_NNP ._.
          RASMCs_NNP were_VBD typically_RB between_IN passages_NNS 2_CD and_CC 7_CD for_IN
          experiments_NNS ._.
        
        
          Recombinant_NNP protein_NN production_NN
          Proteins_NNPS III_NNP 1_CD -_: C_NNP and_CC III_NNP 11_CD -_: C_NNP (_( previously_RB called_VBN III_NNP 
          11_CD )_) were_VBD produced_VBN in_IN bacteria_NNS and_CC
          purified_JJ as_IN described_VBN previously_RB [_NN 2_CD ]_NN ._. III_NNP 1_CD -_: C_NNP
          encompasses_VBZ fibronectin_NN amino_JJ acids_NNS 600_CD -_: 674_CD
          (_( Asn-_NNP Ala-_NNP Pro-_NNP Gln-_NNP ._. ._. ._. Thr-_NNP Ser-_NNP Thr-_NNP Pro_FW )_) ,_, and_CC III_NNP 11_CD -_: C_NNP amino_JJ
          acids_NNS 1_CD ,_, 532_CD -_: 1_CD ,_, 599_CD (_( Leu-_NNP Pro-_NNP Ser-_NNP Ser-_NNP ._. ._. ._. Thr-_NNP Ala-_NNP Val-_NNP Thr_NNP )_) ,_,
          according_VBG to_TO the_DT previously_RB published_VBN numbering_VBG method_NN [_NN
          52_CD ]_NN ._. The_DT recombinant_JJ proteins_NNS were_VBD expressed_VBN by_IN the_DT
          pQE-_NN 12_CD vector_NN ,_, which_WDT places_VBZ a_DT 6_CD -_: His_PRP$ coding_VBG sequence_NN at_IN
          the_DT C-_NNP terminus_JJ of_IN each_DT protein_NN ._. The_DT proteins_NNS were_VBD
          purified_JJ on_IN Ni-agarose_NNP columns_NNS and_CC were_VBD >_NN 98_CD %_NN pure_JJ as_IN
          judged_VBN by_IN SDS-PAGE_NNP and_CC coomassie_NN staining_VBG ._. Stock_NN protein_NN
          solutions_NNS were_VBD typically_RB 700_CD μM_NN for_IN III_NNP 1_CD -_: C_NNP and_CC 520_CD μM_NN for_IN
          III_NNP 11_CD -_: C_NNP in_IN PBS_NNP ._.
          Anti-_NNP III_NNP 1_CD -_: C_NNP antibodies_NNS were_VBD produced_VBN by_IN immunizing_VBG
          rabbits_NNS with_IN III_NNP 1_CD -_: C_NNP ._. After_IN one_CD month_NN the_DT rabbits_NNS were_VBD
          boosted_VBN and_CC serum_NN samples_NNS were_VBD collected_VBN every_DT two_CD weeks_NNS ._.
          The_DT rabbit_NN serum_NN was_VBD applied_VBN to_TO an_DT affinity_NN column_NN to_TO
          purify_NN the_DT anti-_NN III_NNP 1_CD -_: C_NNP antibodies_NNS ._. In_IN order_NN to_TO avoid_VB
          purifying_VBG antibodies_NNS to_TO the_DT 6_CD -_: His_PRP$ tag_NN in_IN III_NNP 1_CD -_: C_NNP ,_, the_DT
          affinity_NN column_NN was_VBD made_VBN with_IN a_DT GST_NNP fusion_NN protein_NN ._. The_DT 1_CD
          sttype_NN III_NNP repeat_NN of_IN fibronectin_NN was_VBD expressed_VBN as_IN a_DT
          fusion_NN protein_NN coupled_VBN to_TO GST_NNP ,_, and_CC this_DT GST-_NNP 3_CD FN_NNP 1_CD fusion_NN
          protein_NN was_VBD coupled_VBN to_TO Sepharose_NNP and_CC used_VBN in_IN affinity_NN
          purification_NN ._. Bound_NNP antibodies_NNS were_VBD eluted_JJ with_IN 100_CD mM_NN
          triethylamine_NN ,_, pH_NN 11_CD ._. 5_LS and_CC the_DT pH_NN was_VBD neutralized_VBN with_IN 1_CD
          M_NNP Tris_NNP ,_, pH_NN 8_CD ;_: (_( the_DT antibody_NN concentration_NN was_VBD 0_CD ._. 4_CD mg_NN /_NN ml_NN )_) ._.
          BSA_NNP (_( 0_CD ._. 5_LS mg_NN /_NN ml_NN )_) was_VBD added_VBN to_TO stabilize_VB the_DT antibody_NN for_IN
          subsequent_JJ handling_NN ._. The_DT antibody_NN prep_NN was_VBD dialyzed_JJ
          extensively_RB against_IN PBS_NNP before_IN use_NN ._.
        
        
          Cell_NNP attachment_NN and_CC spreading_VBG assays_NNS
          For_IN the_DT cell_NN spreading_VBG assay_NN shown_VBN in_IN Fig_NNP ._. 1_LS ,_,
          fibronectin_NN (_( 20_CD μg_NN /_NN ml_NN )_) was_VBD coated_JJ onto_IN 24_CD -_: well_RB dishes_NNS for_IN
          1_CD hr_NN at_IN RT_NNP ._. The_DT wells_NNS were_VBD washed_VBN 3_CD times_NNS with_IN PBS_NNP before_IN
          adding_VBG cells_NNS ._. Growing_VBG RASMCs_NNP were_VBD harvested_VBN by_IN
          trypsinization_NN and_CC collected_VBN into_IN DMEM_NNP +_NN 0_CD ._. 5_CD %_NN BSA_NNP +_NN
          soybean_NN trypsin_NN inhibitor_NN ._. Cells_NNP were_VBD washed_VBN 3_CD times_NNS with_IN
          DMEM_NNP +_NN 0_CD ._. 5_CD %_NN BSA_NNP ,_, then_RB resuspended_JJ at_IN 1_CD ×_NN 10_CD 5_CD cells_NNS /_NN ml_NN in_IN
          DMEM_NNP +_NN 0_CD ._. 5_CD %_NN BSA_NNP ,_, in_IN the_DT absence_NN or_CC presence_NN of_IN 25_CD μM_NN
          III_NNP 1_CD -_: C_NNP or_CC 25_CD μM_NN III_NNP 11_CD -_: C_NNP in_IN the_DT medium_NN ._. Cells_NNP were_VBD seeded_VBN
          onto_IN the_DT wells_NNS (_( 0_CD ._. 5_LS ml_NN /_NN well_RB ,_, ~_NN 30_CD %_NN confluence_NN )_) ,_, placed_VBN in_IN
          a_DT 37_CD °_NN C_NNP incubator_NN and_CC allowed_VBN to_TO adhere_VB for_IN either_DT 7_CD ,_, 15_CD ,_,
          30_CD ,_, 60_CD ,_, 120_CD or_CC 240_CD min_NN ._. Cells_NNP were_VBD then_RB fixed_VBN with_IN 3_CD ._. 7_CD %_NN
          paraformaldehyde_NN ,_, 60_CD mM_NN sucrose_NN in_IN TBS_NNP ,_, followed_VBN by_IN
          staining_VBG with_IN Coomassie_NNP Blue_NNP dye_NN (_( 1_CD mg_NN /_NN ml_NN Coomassie_NNP
          Brilliant_NNP Blue_NNP ,_, 45_CD %_NN MeOH_NNP ,_, 10_CD %_NN acetic_JJ acid_NN )_) ._. Cells_NNP were_VBD
          destained_JJ with_IN water_NN ,_, air-dried_JJ ,_, then_RB photographed_VBN with_IN a_DT
          Leica_NNP DM_NNP IRB_NNP phase_NN microscope_NN connected_VBN to_TO a_DT Polaroid_NNP CCD_NNP
          camera_NN and_CC an_DT Apple_NNP Macintosh_NNP computer_NN for_IN capturing_VBG
          images_NNS ._. To_TO quantitate_NN the_DT amount_NN of_IN spreading_VBG ,_, each_DT image_NN
          was_VBD analyzed_VBN with_IN the_DT NIH_NNP Image_NN 1_CD ._. 61_CD application_NN to_TO
          determine_VB the_DT total_JJ amount_NN of_IN area_NN covered_VBN by_IN cells_NNS and_CC
          this_DT number_NN was_VBD divided_VBN by_IN the_DT total_JJ number_NN of_IN cells_NNS in_IN
          the_DT image_NN to_TO give_VB an_DT average_JJ area_NN per_IN cell_NN (_( in_IN pixels_NNS
          2_CD /_NN cell_NN )_) ._.
          Cell_NNP attachment_NN assays_NNS shown_VBN in_IN Fig_NNP ._. 2_LS and_CC 3_CD were_VBD done_VBN
          essentially_RB as_IN described_VBN previously_RB [_NN 2_CD ]_NN ._. Briefly_NNP ,_,
          fibronectin_NN ,_, III_NNP 1_CD -_: C_NNP or_CC III_NNP 11_CD -_: C_NNP at_IN various_JJ concentrations_NNS
          were_VBD coated_JJ onto_IN 96_CD -_: well_RB dishes_NNS for_IN 1_CD hr_NN at_IN RT_NNP ._. The_DT wells_NNS
          were_VBD then_RB washed_VBN 3_CD times_NNS with_IN PBS_NNP before_IN adding_VBG cells_NNS ._.
          Growing_VBG RASMCs_NNP were_VBD harvested_VBN by_IN trypsinization_NN and_CC
          collected_VBN into_IN DMEM_NNP +_NN 0_CD ._. 5_CD %_NN BSA_NNP +_NN soybean_NN trypsin_NN
          inhibitor_NN ._. Cells_NNP were_VBD washed_VBN 3_CD times_NNS with_IN DMEM_NNP +_NN 0_CD ._. 5_CD %_NN
          BSA_NNP ,_, then_RB resuspended_JJ at_IN 4_CD ×_NN 10_CD 5_CD cells_NNS /_NN ml_NN in_IN DMEM_NNP +_NN 0_CD ._. 5_CD %_NN
          BSA_NNP with_IN or_CC without_IN inhibitors_NNS ,_, as_IN indicated_VBN in_IN the_DT
          figures_NNS ._. Cells_NNP were_VBD seeded_VBN onto_IN the_DT coated_JJ wells_NNS and_CC
          allowed_VBN to_TO adhere_VB for_IN 30_CD min_NN at_IN 37_CD °_NN C_NNP ._. The_DT cells_NNS were_VBD then_RB
          fixed_VBN with_IN 3_CD ._. 7_CD %_NN paraformaldehyde_NN ,_, 60_CD mM_NN sucrose_NN in_IN TBS_NNP ,_,
          followed_VBN by_IN 20_CD %_NN methanol_NN ,_, and_CC staining_VBG in_IN 0_CD ._. 5_CD %_NN crystal_NN
          violet_NN in_IN 20_CD %_NN methanol_NN ._. Stained_NNP cells_NNS were_VBD washed_VBN with_IN
          water_NN and_CC the_DT dye_NN was_VBD solubilized_JJ with_IN 0_CD ._. 1_CD M_NNP sodium_NN
          citrate_NN ,_, pH_NN 4_CD ._. 2_CD ,_, 50_CD %_NN ethanol_NN ._. Attachment_NNP was_VBD quantitated_JJ
          by_IN measuring_VBG the_DT absorbance_NN at_IN 600_CD nm_NN ._.
        
        
          125_CD I_PRP cell_NN surface_NN labeling_VBG and_CC affinity_NN
          chromatography_NN
          The_DT procedure_NN was_VBD a_DT modification_NN of_IN the_DT procedure_NN used_VBN
          to_TO isolate_VB the_DT fibronectin_NN receptor_NN and_CC other_JJ integrins_NNS [_NN
          27_CD 28_CD ]_NN ._. The_DT affinity_NN resins_NNS were_VBD prepared_VBN by_IN coupling_NN
          fibronectin_NN ,_, III_NNP 1_CD -_: C_NNP or_CC III_NNP 11_CD -_: C_NNP to_TO CNBr-activated_NNP
          Sepharose_NNP CL-_NNP 4_CD B_NNP according_VBG to_TO the_DT manufacturer_NN 's_POS
          recommendations_NNS ._. The_DT concentration_NN of_IN protein_NN was_VBD
          typically_RB 4_CD -_: 5_CD mg_NN fibronectin_NN /_NN ml_NN of_IN resin_NN ,_, or_CC 8_CD -_: 10_CD mg_NN
          protein_NN /_NN ml_NN of_IN resin_NN for_IN III_NNP 1_CD -_: C_NNP and_CC III_NNP 11_CD -_: C_NNP ._. Ten_CD 15_CD -_: cm_NN
          dishes_NNS of_IN RASMCs_NNP were_VBD washed_VBN twice_RB with_IN PBS_NNP ,_, then_RB
          harvested_VBN by_IN detachment_NN of_IN cells_NNS in_IN PBS_NNP +_NN 10_CD mM_NN EDTA_NNP ._. The_DT
          cells_NNS were_VBD washed_VBN twice_RB more_JJR with_IN PBS_NNP ,_, then_RB resuspended_JJ
          at_IN 4_CD ×_NN 10_CD 7_CD cells_NNS /_NN ml_NN in_IN PBS_NNP ._. Cells_NNP were_VBD labeled_VBN with_IN 1_CD mCi_NN
          Na_NNP 125_CD I_PRP and_CC lactoperoxidase-_NN H_NNP 
          2_CD O_NNP 
          2_CD ,_, as_RB previously_RB described_VBD [_NN 27_CD ]_NN ._.
          After_IN labeling_VBG the_DT cell_NN pellet_NN was_VBD washed_VBN with_IN ice-cold_JJ
          PBS_NNP +_NN NaN_NNP 
          3_CD ,_, then_RB lysed_JJ in_IN 2_CD volumes_NNS of_IN OG_NNP
          Lysis_NNP Buffer_NNP (_( 200_CD mM_NN octylglucoside_NN ,_, 1_CD mM_NN CaCl_NNP 
          2_CD ,_, 1_CD mM_NN MgCl_NNP 
          2_CD ,_, TBS_NNP ,_, PMSF_NNP )_) at_IN 4_CD °_NN C_NNP ._. The_DT lysate_NN was_VBD
          spun_VBN at_IN 14_CD ,_, 000_CD ×_NN g_SYM for_IN 15_CD min_NN at_IN 4_CD °_NN C_NNP ,_, and_CC the_DT supernatant_NN
          was_VBD used_VBN for_IN affinity_NN chromatography_NN ._. Lysate_NNP was_VBD applied_VBN
          to_TO the_DT affinity_NN columns_NNS (_( 0_CD ._. 2_LS ml_NN lysate_NN was_VBD applied_VBN to_TO 0_CD ._. 1_CD
          ml_NN affinity_NN matrix_NN bed_NN volume_NN )_) ,_, flow_NN through_IN fractions_NNS
          were_VBD collected_VBN and_CC passed_VBN over_IN the_DT columns_NNS twice_RB more_JJR ._.
          Columns_NNP were_VBD washed_VBN with_IN 10_CD column_NN volumes_NNS of_IN Wash_NNP Buffer_NNP
          (_( 40_CD mM_NN octylglucoside_NN ,_, 1_CD mM_NN CaCl_NNP 
          2_CD ,_, 1_CD mM_NN MgCl_NNP 
          2_CD ,_, TBS_NNP )_) ,_, before_IN elution_NN of_IN bound_VBN
          protein_NN with_IN 10_CD mM_NN EDTA_NNP in_IN Wash_NNP Buffer_NNP ._. Samples_NNP from_IN the_DT
          final_JJ wash_NN and_CC eluted_JJ samples_NNS were_VBD separated_JJ on_IN 4_CD -_: 20_CD %_NN
          gradient_NN Novex_NNP gels_NNS ,_, the_DT gels_NNS were_VBD dried_VBN and_CC exposed_VBN to_TO
          phosphorimager_NN cassette_NN and_CC the_DT radioactive_JJ signal_NN was_VBD
          measured_VBN with_IN a_DT Storm_NN phosphorimager_NN instrument_NN ._.
        
        
          MAPK_NNP assay_NN and_CC immunoblotting_VBG
          Wells_NNP of_IN a_DT 6_CD -_: well_RB plate_NN were_VBD coated_VBN with_IN either_DT 20_CD
          μg_NN /_NN ml_NN fibronectin_NN ,_, 25_CD μM_NN III_NNP 1_CD -_: C_NNP or_CC 25_CD μM_NN III_NNP 11_CD -_: C_NNP for_IN 1_CD
          hr_NN at_IN RT_NNP ._. Wells_NNP were_VBD washed_VBN 3_CD times_NNS with_IN PBS_NNP before_IN
          adding_VBG cells_NNS ._. Growing_VBG RASMCs_NNP were_VBD harvested_VBN by_IN
          trypsinization_NN and_CC collected_VBN into_IN DMEM_NNP +_NN 0_CD ._. 5_CD %_NN BSA_NNP +_NN
          soybean_NN trypsin_NN inhibitor_NN ._. Cells_NNP were_VBD washed_VBN 3_CD times_NNS with_IN
          DMEM_NNP +_NN 0_CD ._. 5_CD %_NN BSA_NNP ,_, then_RB resuspended_JJ at_IN 3_CD ×_NN 10_CD 5_CD cells_NNS /_NN ml_NN in_IN
          DMEM_NNP +_NN 0_CD ._. 5_CD %_NN BSA_NNP with_IN or_CC without_IN integrin_NN blocking_VBG agents_NNS
          or_CC other_JJ additions_NNS ,_, as_IN described_VBN in_IN the_DT figure_NN legends_NNS ._.
          Cells_NNP were_VBD either_CC left_VBN in_IN suspension_NN (_( for_IN suspended_VBN and_CC
          PDGF_NNP stimulated_VBN samples_NNS )_) or_CC were_VBD seeded_VBN onto_IN the_DT coated_JJ
          wells_NNS (_( 1_CD ml_NN per_IN well_RB )_) and_CC allowed_VBN to_TO adhere_VB for_IN 30_CD min_NN at_IN
          37_CD °_NN C_NNP ,_, or_CC for_IN the_DT times_NNS indicated_VBD in_IN the_DT figure_NN legend_NN
          (_( Fig_NNP ._. 5_LS )_) ._. The_DT cells_NNS stimulated_VBN with_IN PDGF_NNP (_( 2_CD ng_NN /_NN ml_NN
          PDGF-BB_NNP )_) received_VBD the_DT growth_NN factor_NN 10_CD min_NN before_IN
          collecting_VBG the_DT cells_NNS for_IN lysis_NNS ,_, while_IN the_DT other_JJ samples_NNS
          received_VBD no_DT growth_NN factor_NN or_CC serum_NN ._. After_IN the_DT adhesion_NN
          period_NN plates_NNS were_VBD placed_VBN on_IN ice_NN ,_, unattached_JJ cells_NNS were_VBD
          collected_VBN and_CC spun_VBN down_RB ,_, while_IN cell_NN monolayers_NNS were_VBD
          washed_VBN once_RB with_IN ice_NN cold_JJ PBS_NNP then_RB lysed_JJ with_IN SDS-PAGE_NNP
          sample_NN buffer_NN (_( 100_CD μl_NN /_NN well_RB )_) ._. Centrifuged_NNP pellets_NNS of_IN
          unattached_JJ cells_NNS were_VBD combined_VBN with_IN the_DT appropriate_JJ
          monolayer_NN lysate_NN sample_NN and_CC the_DT samples_NNS were_VBD heated_VBN to_TO
          100_CD °_NN C_NNP for_IN 5_CD min_NN ._. Samples_NNP were_VBD separated_JJ on_IN 4_CD -_: 20_CD %_NN gradient_NN
          Novex_NNP gels_NNS ,_, transferred_VBN to_TO Immobilon_NNP P_NN membranes_NNS ,_, blocked_VBN
          with_IN 5_CD %_NN nonfat_JJ dry_JJ milk_NN in_IN TBS-Tween_NNP ,_, then_RB probed_JJ with_IN
          anti-phospho-p_JJ 44_CD /_NN 42_CD MAPK_NNP antibody_NN according_VBG to_TO the_DT
          manufacturer_NN 's_POS recommendations_NNS ._. Blots_NNP were_VBD then_RB stripped_VBN
          in_IN Stripping_NNP Buffer_NNP (_( 2_CD %_NN SDS_NNP ,_, 100_CD mM_NN β-mercaptoethanol_JJ ,_,
          62_CD ._. 5_LS mM_NN Tris_NNP ,_, pH_NN 6_CD ._. 7_CD )_) at_IN 50_CD °_NN C_NNP for_IN 30_CD min_NN ,_, washed_VBD 4_CD times_NNS
          with_IN TBS-Tween_NNP ,_, blocked_VBN with_IN 5_CD %_NN nonfat_JJ dry_JJ milk_NN in_IN
          TBS-Tween_NNP ,_, then_RB probed_JJ with_IN anti-p_JJ 44_CD /_NN 42_CD ERK_NNP antibody_NN
          according_VBG to_TO the_DT manufacturer_NN 's_POS recommendations_NNS ._. All_DT
          blots_NNS were_VBD developed_VBN with_IN the_DT ECL_NNP plus_CC reagent_NN and_CC
          exposed_VBN to_TO Hyperfilm_NNP ._. For_IN both_DT antibodies_NNS the_DT typical_JJ
          exposure_NN times_NNS were_VBD under_IN 5_CD min_NN ._.
        
        
          Heparitinase_NNP treatment_NN of_IN cells_NNS and_CC lysates_NNS
          6_CD well_RB plates_NNS were_VBD coated_VBN with_IN either_DT fibronectin_NN ,_,
          III_NNP 1_CD -_: C_NNP or_CC III_NNP 11_CD -_: C_NNP as_IN described_VBN above_IN ._. Growing_VBG RASMCs_NNP
          were_VBD harvested_VBN by_IN trypsinization_NN and_CC washed_VBN in_IN DMEM_NNP +_NN BSA_NNP
          as_IN described_VBN above_IN ._. For_IN GAGase_NNP treatment_NN of_IN intact_JJ cells_NNS ,_,
          the_DT cells_NNS remained_VBD in_IN suspension_NN and_CC received_VBD either_CC no_DT
          enzyme_NN or_CC 0_CD ._. 1_CD u_NN /_NN ml_NN heparitinase_NN or_CC 0_CD ._. 1_CD u_NN /_NN ml_NN
          chondroitinase_NN ABC_NNP for_IN 1_CD hr_NN at_IN 37_CD °_NN C_NNP with_IN constant_JJ gentle_JJ
          rotation_NN ._. Cells_NNP were_VBD then_RB plated_JJ onto_IN precoated_JJ dishes_NNS
          and_CC processed_VBN for_IN immunoblotting_VBG with_IN anti-phospho-p_JJ 44_CD /_NN 42_CD
          MAPK_NNP antibody_NN as_IN described_VBN above_IN ._. Alternatively_RB ,_, after_IN
          heparitinase_NN digestion_NN cells_NNS were_VBD lysed_JJ directly_RB in_IN SDS_NNP
          sample_NN buffer_NN and_CC analyzed_VBN by_IN immunoblotting_VBG with_IN the_DT
          3_CD G_NNP 10_CD mAb_NN (_( essentially_RB as_IN described_VBN above_IN for_IN
          anti-phospho-p_JJ 44_CD /_NN 42_CD MAPK_NNP immunoblotting_VBG )_) ._.
          For_IN GAGase_NNP treatment_NN of_IN cell_NN lysates_NNS ,_, cells_NNS were_VBD lysed_JJ
          on_IN ice_NN in_IN NP_NNP 40_CD Lysis_NNP buffer_NN (_( 1_CD %_NN Nonidet_NNP P_NN 40_CD ,_, 150_CD mM_NN
          NaCl_NNP ,_, 50_CD mM_NN Tris_NNP ,_, pH_NN 8_CD ._. 0_CD )_) plus_CC protease_NN inhibitors_NNS
          (_( Complete_JJ ™_NN protease_NN inhibitor_NN cocktail_NN )_) at_IN 2_CD ×_NN 10_CD
          6_CD cells_NNS /_NN ml_NN ._. Insoluble_NNP material_NN was_VBD removed_VBN by_IN
          centrifugation_NN at_IN 14_CD ,_, 000_CD ×_NN g_SYM for_IN 15_CD min_NN at_IN 4_CD °_NN C_NNP ._. Lysate_NNP
          was_VBD prepared_VBN for_IN heparitinase_NN treatment_NN by_IN adding_VBG CaCl_NNP 
          2_CD to_TO 10_CD μM_NN final_JJ concentration_NN ._.
          Heparitinase_NNP was_VBD added_VBN to_TO 0_CD ._. 1_CD u_NN /_NN ml_NN final_JJ concentration_NN
          and_CC the_DT lysate_NN was_VBD incubated_JJ at_IN 37_CD °_NN C_NNP for_IN 1_CD hr_NN ._. The_DT lysate_NN
          was_VBD then_RB applied_VBN to_TO affinity_NN chromatography_NN columns_NNS as_IN
          described_VBN below_IN ._.
        
        
          35_CD SO_NNP 4_CD labeling_VBG and_CC affinity_NN chromatography_NN
          Growing_VBG RASMCs_NNP labeled_VBD for_IN 20_CD hr_NN at_IN 37_CD °_NN C_NNP with_IN 200_CD
          μCi_NN /_NN ml_NN 35_CD S_NNP 04_CD in_IN DMEM_NNP +_NN 10_CD %_NN dialyzed_JJ FCS_NNP +_NN Pen-_NNP Strep_NNP ._.
          Cells_NNP were_VBD placed_VBN on_IN ice_NN ,_, washed_VBD once_RB with_IN PBS_NNP ,_, then_RB
          lysed_JJ in_IN NP_NNP 40_CD Lysis_NNP buffer_NN as_IN described_VBN above_IN ._. III_NNP 1_CD -_: C_NNP and_CC
          III_NNP 11_CD -_: C_NNP columns_NNS were_VBD produced_VBN as_IN described_VBN above_IN ._. Cell_NNP
          lysates_NNS were_VBD applied_VBN to_TO III_NNP 1_CD -_: C_NNP or_CC III_NNP 11_CD -_: C_NNP columns_NNS
          (_( typically_RB 500_CD μl_NN lysate_NN was_VBD applied_VBN to_TO 250_CD μl_NN affinity_NN
          matrix_NN bed_NN volume_NN )_) ,_, flow_NN through_IN fractions_NNS were_VBD collected_VBN
          and_CC passed_VBN over_IN the_DT columns_NNS twice_RB more_JJR ._. The_DT final_JJ flow_NN
          through_IN fractions_NNS were_VBD then_RB collected_VBN ._. Columns_NNP were_VBD
          washed_VBN with_IN 10_CD column_NN volumes_NNS of_IN NP_NNP 40_CD Lysis_NNP buffer_NN ,_, then_RB
          bound_VBN material_NN was_VBD removed_VBN by_IN boiling_VBG the_DT Sepharose_NNP beads_NNS
          in_IN 2_CD column_NN volumes_NNS of_IN SDS_NNP sample_NN buffer_NN ._. Alternatively_RB ,_,
          the_DT bound_VBN material_NN was_VBD first_JJ eluted_JJ with_IN 2_CD column_NN volumes_NNS
          of_IN 8_CD M_NNP urea_NN buffer_NN (_( 8_CD M_NNP urea_NN ,_, 0_CD ._. 1_CD M_NNP NaH_NNP 
          2_CD PO_NNP 
          4_CD ,_, 10_CD mM_NN Tris_NNP ,_, pH_NN 8_CD ._. 0_CD )_) ,_, followed_VBN by_IN
          washing_VBG with_IN 10_CD column_NN volumes_NNS of_IN NP_NNP 40_CD Lysis_NNP buffer_NN ,_, and_CC
          then_RB removing_VBG any_DT remaining_VBG bound_VBN material_NN by_IN boiling_VBG the_DT
          Sepharose_NNP beads_NNS in_IN SDS_NNP sample_NN buffer_NN ._. Samples_NNP were_VBD
          separated_JJ on_IN 4_CD -_: 20_CD %_NN Novex_NNP SDS-PAGE_NNP gels_NNS ,_, the_DT gels_NNS were_VBD
          fixed_VBN and_CC dried_VBN and_CC the_DT radioactive_JJ material_NN was_VBD detected_VBN
          by_IN using_VBG a_DT phosphorimager_NN ._.
        
      
    
  
